Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov 30:26:55-61.
doi: 10.1016/j.ctro.2020.11.014. eCollection 2021 Jan.

Marker-less online MR-guided stereotactic body radiotherapy of liver metastases at a 1.5 T MR-Linac - Feasibility, workflow data and patient acceptance

Affiliations

Marker-less online MR-guided stereotactic body radiotherapy of liver metastases at a 1.5 T MR-Linac - Feasibility, workflow data and patient acceptance

Cihan Gani et al. Clin Transl Radiat Oncol. .

Abstract

Introduction: Stereotactic body radiotherapy (SBRT) is an established ablative treatment for liver tumors with excellent local control rates. Magnetic resonance imaging guided radiotherapy (MRgRT) provides superior soft tissue contrast and may therefore facilitate a marker-less liver SBRT workflow. The goal of the present study was to investigate feasibility, workflow parameters, toxicity and patient acceptance of MRgSBRT on a 1.5 T MR-Linac.

Methods: Ten consecutive patients with liver metastases treated on a 1.5 T MR-Linac were included in this prospective trial. Tumor delineation was performed on four-dimensional computed tomography scans and both exhale triggered and free-breathing T2 MRI scans from the MR-Linac. An internal target volume based approach was applied. Organ at risk constraints were based on the UKSABR guidelines (Version 6.1). Patient acceptance regarding device specific aspects was assessed and toxicity was scored according to the common toxicity criteria of adverse events, version 5.

Results: Nine of ten tumors were clearly visible on the 1.5 T MR-Linac. No patient had fiducial markers placed for treatment. All patients were treated with three or five fractions. Median dose to 98% of the gross tumor volume was 38.5 Gy. The median time from "patient identity check" until "beam-off" was 31 min. Median beam on time was 9.6 min. Online MRgRT was well accepted in general and no treatment had to be interrupted on patient request. No event of symptomatic radiation induced liver disease was observed after a median follow-up of ten month (range 3-17 months).

Conclusion: Our early experience suggests that online 1.5 T MRgSBRT of liver metastases represents a promising new non-invasive marker-free treatment modality based on high image quality, clinically reasonable in-room times and high patient acceptance. Further studies are necessary to assess clinical outcome, to validate advanced motion management and to explore the benefit of online response adaptive liver SBRT.

PubMed Disclaimer

Conflict of interest statement

The Department of Radiation Oncology Tübingen receives within the frame of research agreements financial and technical support as well as sponsoring for travels and scientific symposia from: Elekta AB (Stockholm, Sweden), Philips GmbH, Siemens, PTW Freiburg Physikalisch-Technische Werkstätten Dr. Pychlau GmbH.

Figures

Fig. 1
Fig. 1
Representative transversal scans of the first three patients. Shown are non-contrast enhanced simulations computed tomography scans, exhale triggered T2 scans on the 1.5 T MR-Linac and non-triggered T2 scans from the online workflow on the 1.5 T MR-Linac. SIM-simulation.
Fig. 2
Fig. 2
Patient acceptance of various aspects of online MRgSBRT.

References

    1. Engstrand J., Nilsson H., Strömberg C., Jonas E., Freedman J. Colorectal cancer liver metastases – a population-based study on incidence, management and survival. BMC Cancer. 2018;18(1) doi: 10.1186/s12885-017-3925-x. - DOI - PMC - PubMed
    1. Al Bandar M.H., Kim N.K. Current status and future perspectives on treatment of liver metastasis in colorectal cancer (Review) Oncol Rep. 2017;37:2553–2564. - PubMed
    1. Jackson W.C., Tao Y., Mendiratta-Lala M., Bazzi L., Wahl D.R., Schipper M.J. Comparison of stereotactic body radiation therapy and radiofrequency ablation in the treatment of intrahepatic metastases. Int J Radiat Oncol Biol Phys. 2018;100(4):950–958. - PMC - PubMed
    1. Goodman K.A., Kavanagh B.D. Stereotactic body radiotherapy for liver metastases. Semin Radiat Oncol. 2017;27(3):240–246. - PubMed
    1. Ohri N., Tomé W.A., Méndez Romero A., Miften M., Ten Haken R.K., Dawson L.A. Local control after stereotactic body radiation therapy for liver tumors. Int J Radiat Oncol Biol Phys. 2018 - PMC - PubMed

LinkOut - more resources